COVIDNews CEPTON-INATO #2
10 April 2020 -
By Marc-Olivier Bévierre
The number of COVID-19 clinical trials is continually growing, with Europe and the US now in the driver’s seat. here is our second weekly newsletter, with a special focus on the most studied drug so far, hydroxychloroquine.
Copyright CEPTON and INATO
CEPTON Strategies news
Here are all the reports and analysis we published along with the press articles about us
CEPTON is the author of many publications in the field of healthcare and pharmaceuticals and our partners are often interviewed by the specialized press.
